Innovate Biopharmaceuticals (NASDAQ: INNT) is one of 548 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Innovate Biopharmaceuticals to similar companies based on the strength of its earnings, valuation, institutional ownership, dividends, analyst recommendations, risk and profitability.
This is a summary of current ratings and recommmendations for Innovate Biopharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innovate Biopharmaceuticals Competitors||4553||13028||27681||994||2.54|
Innovate Biopharmaceuticals currently has a consensus target price of $35.00, suggesting a potential upside of 1,791.89%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.26%. Given Innovate Biopharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Innovate Biopharmaceuticals is more favorable than its peers.
Earnings and Valuation
This table compares Innovate Biopharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Innovate Biopharmaceuticals||$4.07 million||-$24.16 million||N/A|
|Innovate Biopharmaceuticals Competitors||$2.15 billion||$228.73 million||-3.55|
Innovate Biopharmaceuticals’ peers have higher revenue and earnings than Innovate Biopharmaceuticals.
Risk & Volatility
Innovate Biopharmaceuticals has a beta of -3.54, indicating that its stock price is 454% less volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals’ peers have a beta of 1.38, indicating that their average stock price is 38% more volatile than the S&P 500.
This table compares Innovate Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innovate Biopharmaceuticals Competitors||-1,760.46%||-120.17%||-28.09%|
Insider and Institutional Ownership
11.9% of Innovate Biopharmaceuticals shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.1% of Innovate Biopharmaceuticals shares are held by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Innovate Biopharmaceuticals peers beat Innovate Biopharmaceuticals on 7 of the 12 factors compared.
About Innovate Biopharmaceuticals
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.